Let us discuss the COVID-19 vaccine for children

Sonia Gulia; Kusum K. Rohilla; Mahendra Kumar; Raman Sharma

doi:10.5455/NJPPP.2025.v15.i6.16

2026, Vol: 16, Issue: 1

16 / 1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Letter to the Editor

Natl J Physiol Pharm Pharmacol. 2025; 15(6): 416-420

doi: 10.5455/NJPPP.2025.v15.i6.16

Let us discuss the COVID-19 vaccine for children

Sonia Gulia, Kusum K. Rohilla, Mahendra Kumar, Raman Sharma.

Abstract
A large number of COVID-19 vaccinations are now being licensed for use in children, even though the majority of them are exclusively intended for adults (18 years and older). When creating their COVID-19 immunization policies and programs, countries should consider the individual and population benefits of immunizing children and adolescents in their unique epidemiological. Immunizing children and adolescents is less urgent than immunizing older individuals, those with chronic health conditions, and healthcare professionals because they typically have milder disease compared to adults, unless they are in a group at increased risk of severe COVID-19.

Key words: Immunization; COVID-19 vaccine; Children; Adolescents.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Sonia Gulia Articles by Kusum K. Rohilla Articles by Mahendra Kumar Articles by Raman Sharma
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. Natl J Physiol Pharm Pharmacol. 2025; 15(6): 416-420. doi:10.5455/NJPPP.2025.v15.i6.16

Web Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. https://www.njppp.com/?mno=125882 [Access: June 27, 2026]. doi:10.5455/NJPPP.2025.v15.i6.16

AMA (American Medical Association) Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. Natl J Physiol Pharm Pharmacol. 2025; 15(6): 416-420. doi:10.5455/NJPPP.2025.v15.i6.16

Vancouver/ICMJE Style

Gulia S, Rohilla KK, Kumar M, Sharma R. Let us discuss the COVID-19 vaccine for children. Natl J Physiol Pharm Pharmacol. (2025), [cited June 27, 2026]; 15(6): 416-420. doi:10.5455/NJPPP.2025.v15.i6.16

Harvard Style

Gulia, S., Rohilla, . K. K., Kumar, . M. & Sharma, . R. (2025) Let us discuss the COVID-19 vaccine for children. Natl J Physiol Pharm Pharmacol, 15 (6), 416-420. doi:10.5455/NJPPP.2025.v15.i6.16

Turabian Style

Gulia, Sonia, Kusum K. Rohilla, Mahendra Kumar, and Raman Sharma. 2025. Let us discuss the COVID-19 vaccine for children. National Journal of Physiology, Pharmacy and Pharmacology, 15 (6), 416-420. doi:10.5455/NJPPP.2025.v15.i6.16

Chicago Style

Gulia, Sonia, Kusum K. Rohilla, Mahendra Kumar, and Raman Sharma. "Let us discuss the COVID-19 vaccine for children." National Journal of Physiology, Pharmacy and Pharmacology 15 (2025), 416-420. doi:10.5455/NJPPP.2025.v15.i6.16

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Gulia, S., Rohilla, . K. K., Kumar, . M. & Sharma, . R. (2025) Let us discuss the COVID-19 vaccine for children. National Journal of Physiology, Pharmacy and Pharmacology, 15 (6), 416-420. doi:10.5455/NJPPP.2025.v15.i6.16

About National Journal of Physiology, Pharmacy and Pharmacology

About the JournalThe National Journal of Physiology, Pharmacy and Pharmacology (NJPPP) is a peer-reviewed, open-access journal dedicated to advancing rese ... Read more.

For best results, please use Internet Explorer or Google Chrome.

Contact Information

Eldaghayes Publisher

www.eldaghayes.com

All correspondence should be addressed to:

National Journal of Physiology, Pharmacy and Pharmacology

Email: info@eldaghayes.com

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article